Kornimate/medical-research-clean huggingface dataset:
refractive and corneal topographic characteristics in upper egypt children with high cylinder

Conditions: Corneal Ectasia

Summary: refractive and corneal topographic characteristics in upper egypt children with high cylinder: a cross sectional study

astigmatism is defined as, a refractive condition in which refractive light fails to form a focus on the retina, it accounts for about 13% of refractive errors. it is frequent and correctable cause of visual impairment in children whether associated with spherical errors or not. astigmatism, is the refractive error of the highest clinical importance, being associated with reduced visual acuity with subsequent development of refractive amblyopia. high cylinder in children belong to areas of hot and dry climates, makes exclusion of keratoconus is mandatory. population in the african continent, the mediterranean countries, central and south america, and the indian subcontinent usually have the habit of eye rubbing because of bothering symptoms of dryness, itching, atopy, allergy and vernal keratoconjunctivitis, which is the severe form of allergic conjunctivitis. eye rubbing causes thinning of keratocyte and increases the prevalence of keratoconus. keratoconus in children (diagnosed before the age of eighteenth) is less common but more aggressive than that of the adults, due to the dynamic nature of the young cornea. few studies in the literature reported the prevalence and incidence of keratoconus in children. pentacam is an advanced instrument with a rotating scheimpflug camera for scanning the anterior and posterior corneal surfaces. its measurements of the corneal thickness and posterior elevation have been proved to be of high reproducibility and repeatability.

Eligibility criteria:
inclusion criteria: - upper egypt children with high cylinder(refractive errorr). exclusion criteria: * children below age of 7 years old (uncooperative), patients above age of 18 years old.patients with corneal scars
demographic differences in patients with abdominal aortic aneurysm and surgical features of treatment

Conditions: Aortic Aneurysm, Abdominal

Summary: the study of demographics and risk factors for abdominal aortic aneurysms, allows to individualize treatment approaches. determining of the results of treatment of patients who requires a late open conversion after evar will allow to develop the surgical approach and the selection of the optimal type of surgical treatment. determination of genetic polymorphisms will reduce the number of postoperative complications by predicting of possible complications in the long term period.


Eligibility criteria:
inclusion criteria: * infrarenal aortic aneurysm exclusion criteria: * other aneurysms
effects of rf microneedle on photoaging skin

Conditions: Pigmentation; Pigmentation Disorder

Summary: melasma relapse is almost common after discontinuation of conventional treatment. recent studies have suggested that photoaging dermis is main pathomechanism of melasma emphasizing stromal targeting therapy. therefore, we investigated maintenance effect of microneedle radiofrequency (rf) for melasma treatment.


Eligibility criteria:
inclusion criteria: * adult more than 19 years old * melasma clinically diagnosed by three dermatologists exclusion criteria: * aesthetic medical procedures in three months prior to the study * use of topical depigmenting agents in three months prior to the study * pregnant or lactating
study of hepatitis c virus (hcv) entry inhibitor in liver transplant recipients with hcv infection

Conditions: Hepatitis C Infection

Summary: this study will test the safety and tolerability of hcv entry inhibitor itx 5061 in liver transplant recipients with hepatitis c infection. the investigators hypothesize that itx 5061 oral monotherapy will be safe in adults during and after liver transplantation and that therapy will also inhibit hcv infection of newly transplanted livers in adults with prior hcv infection.

all subjects will receive 28 days of itx 5061 beginning at the time of transplant. dosing of itx 5061 is as follows: day of transplant prior to surgery: itx 5061 300 mg day of transplant following surgery: itx 5061 300 mg post-operative days 1-6: itx 5061 300 mg post-operative days 7-27: itx 5061 150 mg subjects will be monitored for hcv rna levels, hdl cholesterol and itx 5061 drug concentration levels. a liver biopsy will be performed at 6 months post-transplant to assess for histological signs of hcv recurrence.

Eligibility criteria:
inclusion criteria: * age 18-72 * patients accepted onto waiting list for liver transplantation for hcv related liver disease and receiving a deceased donor liver allograft * hcv rna (+) at time of listing for transplantation. all hcv genotypes will be eligible * patients with hcc and those receiving hepatitis b core (+) donor livers will be eligible * standard immunosuppression protocol with tacrolimus, corticosteroid taper, and mycophenolate mofetil exclusion criteria: * viral co-infection (hbv/hiv) * receipt of a hcv (+) donor allograft * patients undergoing retransplantation for recurrent hcv * multivisceral transplantation * patients receiving anti-viral therapy at the time of lt * live donor liver transplantation

Keywords: hepatitis c virus infection liver transplantation
a longitudinal study of choroidal changes after cataract surgery in eyes with diabetic retinopathy

Conditions: Optical Coherence Tomography; Diabetic Retinopathy; Choroid

Summary: to determine the influence of phacoemulsification on choroidal vasculature in patients with diabetic retinopathy (dr) undergoing cataract surgery

to determine the influence of phacoemulsification on choroidal vasculature in patients with diabetic retinopathy (dr) undergoing cataract surgery through the follow-up of choroidal thickness (ct) and choroidal vascularity index (cvi) using swept-source optical coherence tomography (ss-oct) system.

Eligibility criteria:
inclusion criteria: * aged⩾40years; intraocular pressure (iop) \< 21 mm hg in both eyes, spherical refractive error\<6 diopters spherical equivalent. exclusion criteria: * previous retinal surgery, glaucoma, uveitis, age-related macular degeneration, arterial or vein occlusions, macular hole, or other ocular diseases that could interfere the ct and/or cvi measurement, severe systemic diseases, such as uncontrolled hypertension, obstructive sleep apnea, etc.

Keywords: diabetic choroidopathy diabetic retinopathy choroidal vascularity index choroidal thickness
single vs. dual antiplatelet therapy in elderly or hbr patients undergoing percutaneous intervention with dcb

Conditions: Coronary Disease; Heart Diseases; Cardiovascular Diseases; Myocardial Ischemia; Atherosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Coronary Artery Disease; Acute Coronary Syndrome; Coronary Stenosis; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; MTOR Inhibitors; Protein Kinase Inhibitors; Physiological Effects of Drugs; Immunosuppressive Agents; Antineoplastic Agents; High Bleeding Risk; Single Antiplatelet Therapy; Dual Antiplatelet Therapy; Cyclooxygenase Inhibitors; P2Y12 Inhibitor; Platelet Aggregation Inhibitors; Aspirin; Clopidogrel

Summary: international multicenter, investigator-driven, open-label, randomized (1:1) clinical trial to observe and evaluate the rate of ischemic and bleeding adverse events of a single antiplatelet regimen (sapt) since the time of pci with latest generation dcb in elderly or hbr population with stable or unstable coronary syndromes.

the purpose of piccoleto iv study is to observe and evaluate the efficacy and safety of a single antiplatelet therapy (sapt) after successful dcb angioplasty with essential pro (drug-coated balloon (ivascular) in native coronary artery disease in vessels with diameter \>=2.0 and \<=4.0 mm as compared to the routine dual antiplatelet therapy (dapt). patients with stable or unstable coronary syndromes will be enrolled in this study.

Eligibility criteria:
inclusion criteria: * successful pci with solo-dcb just performed, in 1, 2 or 3 coronary vessels; * stable or unstable coronary syndromes; * de novo coronary lesions in vessels with diameter \>=2.0 and \<=4.0 mm (visual estimation); * informed consent to participate in the study; * at least one of the following criteria: \>=75 y.o.; high bleeding risk (arc criteria) exclusion criteria: * stent implantation during index or recent (\<6 months) procedure; * patients with known (and untreatable) hypersensitivity or contraindication to aspirin, heparin, clopidogrel, contrast media, which cannot be adequately pre-medicated; * patients participating in another clinical study; - pregnancy at the time of hospitalization; * st-elevation myocardial infarction; * life expectancy \<12 months; * left ventricular ejection fraction \<30%; * visible thrombus at lesion site; * target lesion/vessel with any of the following characteristics: * severe and/or \>270° calcification of the target vessel, also proximal to the lesion (intravascular imaging not mandatory); * left main stem stenosis \>50%; * target lesion is in the left main stem; * chronic total occlusion with anticipated necessity of retrograde approach; * lesion is in a bypass graft.

Keywords: dcb angioplasty paclitaxel antiplatelet treatment single antiplatelet therapy (sapt) dual antiplatelet therapy (dapt) high bleeding risk (hbr) mace native cad stable or unstable coronary syndromes
phase 2 safety and efficacy study of tulisokibart (mk-7240/pra023) in subjects with systemic sclerosis associated with interstitial lung disease (ssc-ild) (mk-7240-007)

Conditions: Diffuse Cutaneous Systemic Sclerosis; Interstitial Lung Disease

Summary: the purpose of this study is to assess the safety and efficacy of tulisokibart in participants with ssc-ild.


Eligibility criteria:
inclusion criteria: * has confirmed diagnosis of systemic sclerosis with onset of disease ≤ 5 years ago. * has diffuse cutaneous scleroderma * has systemic sclerosis related interstitial lung disease confirmed by hrct * fvc ≥ 45% of predicted normal * diffusing capacity of lung for carbon monoxide (dlco)≥ 45% of predicted normal * if on background therapy, meets stable dosing requirements for nintedanib, mycophenolate mofetil (mmf), methotrexate (mtx) or azathioprine, and corticosteroids * women of childbearing potential are eligible to participate if not pregnant or breastfeeding and either willing to use an acceptable contraceptive method or sexually abstinent * able to provide written informed consent and understand and comply with the requirements of the study exclusion criteria: * has an airway obstruction per pulmonary function test (pft) or clinically significant pulmonary arterial hypertension * has current clinical diagnosis of another inflammatory connective tissue disease * has any active infections, a serious infection within the past 3 months, or chronic bacterial infection * is a current smoker or smoking within 6 months of screening * has any concomitant medical conditions that, in the opinion of the investigator, might place them in unacceptable risk for participation in the study * meets the protocol criteria for important laboratory exclusion criteria

Keywords: athena ssc-ild athena diffuse cutaneous scleroderma interstitial lung disease
use of telemedicine in collaboration between a psychogeriatric unit and nursing homes

Conditions: Dementia; Behavioural Disorders

Summary: the investigators want to evaluate the use of video-conference in the collaboration between the investigators psychogeriatric department and nursing homes. the study aim is to give supervision on a regular basis to the caregivers on a special care unit for patients with dementia with behavioural disturbances during a period of half a year. the investigators want to investigate the impact on caregivers and patients by applying certain tests at baseline, during the intervention and half a year after the intervention.


Eligibility criteria:
inclusion criteria: * being resident in a special care unit for persons with dementia exclusion criteria: * shorter stay than four weeks before inclusion * terminally ill
complement study- a first in human study of metabolic neuromodulation therapy

Conditions: Diabetes; Endocrine, Nutritional and Metabolic Diseases (E00-E89)

Summary: the purpose of this research study is to collect information about a new treatment for type 2 diabetes mellitus (t2dm), using a medical device called the metabolic neuromodulation system which is intended to help regulate blood glucose levels in patients whose (t2dm) is not well controlled despite treatment with multiple medications. the medical device delivers low-level radiofrequency energy through the wall of the blood vessel to the liver to disrupt the nerves that lead to the liver. previous research has shown that disrupting these nerves may lead to a lowering of blood sugar levels.

prospective, first-in-human (fih), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.

Eligibility criteria:
inclusion criteria: * age 18-65 years * uncontrolled t2dm, as evidenced by hba1c levels, on a consistent oral anti-hyperglycemic drug regimen of at least two different drug classes * documented status of stable lifestyle modifications exclusion criteria: * diagnosed type 1 diabetes mellitus * history or diagnosis of proliferative retinopathy or advanced autonomic neuropathy * estimated glomerular filtration rate (gfr) \< 60ml/min/1.73m2

Keywords: type 2 diabetes
brace versus no brace for the treatment of thoracolumbar burst fractures without neurologic injury

Conditions: Thoracolumbar Burst Fractures Without Neurologic Deficit

Summary: braces have been used o treat stable (not requiring surgery) burst fractures with much success. recently questions have been raised in regards to the importance of the brace. some studies have results that suggest a brace is not important in having a good outcome. however, this has never been proven. this study is being conducted to see whether or not wearing a brace is important to having a good outcome.

the purpose of this study is to prospectively compare the outcome between patients randomly assigned to a thoracolumbosacral orthosis (tlso) treatment group or no orthosis (no) treatment group, for the management of an acute ao type a3 thoracolumbar fracture.

Eligibility criteria:
inclusion criteria: * ao a3 burst fracture between t10 and l3 with associated kyphotic deformity \<35 degrees * neurologically intact or isolated nerve root deficit * age 16-60 years * enrollment within 3 days of injury exclusion criteria: * neurological deficit * can not comply with brace wearing (pregnancy/body mass index \>40) * mobilized with or without a brace prior to recruitment * suffered a pathologic or open fracture * alcohol or drug abusers * had previous injury or surgery to the thoracolumbar region * unable to complete the questionnaires
effects of growth hormone on difficult ventilator weaning patients

Conditions: Mechanical Ventilation Complication

Summary: major abdominal surgeries may be followed by postoperative pulmonary complications (ppcs). these complications are common and can cause significant morbidity and mortality. major operations are followed by acute respiratory insufficiency (ri) in 3%-27.4%, which causes prolonged hospital stay, high patient costs, high mortality rate and lower survival rates. the most crucial pulmonary postoperative complication is the prolonged mechanical ventilation and difficult weaning.the rhgh is a synthetic metabolic hormone which improves synthesis of protein, corrects hypoalbumenia, reverses negative nitrogen balance, improves patient nutrition, improves wound healing and promotes recovery of respiratory muscle function. when used for weaning from mechanical ventilation, rhgh reducess the duration of mechanical ventilation time, icu admission period, incidence of vap \& icu mortality.

major abdominal surgeries may be followed by postoperative pulmonary complications (ppcs). these complications are common and can cause significant morbidity and mortality. major operations are followed by acute respiratory insufficiency (ri) in 3%-27.4%, which causes prolonged hospital stay, high patient costs, high mortality rate and lower survival rates. the most crucial pulmonary postoperative complication is the prolonged mechanical ventilation and difficult weaning.the rhgh is a synthetic metabolic hormone which improves synthesis of protein, corrects hypoalbumenia, reverses negative nitrogen balance, improves patient nutrition, improves wound healing and promotes recovery of respiratory muscle function. when used for weaning from mechanical ventilation, rhgh reducess the duration of mechanical ventilation time, icu admission period, incidence of vap \& icu mortality. felbinger et al reported a case of prolonged ventilation with failure of weaning after 42 days; the patient received subcutaneous rhgh (0.3 iu/kg/day) for 20 days in addition to intensive care standard management. they reported improvement of protein metabolism in addition to improvement of respiratory muscle strength, the patient was weaned successfully on the 75th postoperative day.this study assumes a hypothesis that rhgh would help weaning from mechanically ventilated tracheostomized patients.

Eligibility criteria:
inclusion criteria: * patients undergoing major abdominal cancer surgeries. * patients requiring prolonged postoperative ventilation. * patients with multiple failed trials of mechanical ventilation weaning. * asa i and ii patients. exclusion criteria: * history of chronic cardiac,renal or respiratory illness. * septic or septic shock patients on inotropic supports. * fully alert and conscious patients. * asa 3 and 4.

Keywords: recombinant growth hormone difficult ventilator weaning postoperative complications
clinical outcomes of treatment with immunomodulator plus cancer therapies for patients with colorectal cancer

Conditions: Colorectal Cancer

Summary: this study aims to evaluate the survival and treatment outcomes among colorectal cancer patients undergoing anti-cancer treatment, both with and without an immunomodulator.

colorectal cancer (crc) is the third most common cancer worldwide. the clinical outcomes from crc treatments are often unsatisfactory for the majority of patients. the tumor microenvironment (tme) plays an important role to regulate tumor growth, progression, and metastasis and can limit the efficacy of cancer therapies. therefore, targeting tme could provide an efficient approach for cancer treatment. astragalus polysaccharide injection, an immunomodulator, which can stimulate medullary hematopoiesis and enhance immune function. it also can modulate tme. astragalus polysaccharide injection has been approved as a prescription drug for alleviating cancer-related fatigue by the taiwan food and drug administration (tfda). in this retrospective study, we will collect clinical data and survival status of colorectal cancer patients undergoing anti-cancer treatment from their medical records with and without immunomodulator, astragalus polysaccharide injection. it can be used to understand the possible clinical benefit of immunomodulator plus anti-cancer therapies for patients with colorectal cancer, and physicians can refer to these results to give patients the suitable treatment recommendations.

Eligibility criteria:
inclusion criteria: * aged 20 years and older. * patients who have been given a diagnosis of colorectal cancer. * patients had previously initiated anti-cancer therapies between january 1, 2020, and apr 30, 2024. exclusion criteria: * none

Keywords: colorectal cancer astragalus polysaccharides survival
safety, tolerability, and pharmacokinetics of dcr-pdl1 in adults with solid tumors

Conditions: Solid Tumors, Adult

Summary: the study will evaluate the safety, tolerability, and pharmacokinetics of intravenous dcr-pdl1 in adults with solid tumors. participants will be enrolled in one of 4 ascending-dose cohorts. each treatment cycle will consist of multiple intravenous (iv) doses. dose escalation decisions will be based on data collected during the dose-limiting toxicity (dlt) period.


Eligibility criteria:
inclusion criteria: * male or female adults, aged greater than or equal to (≥) 18 years. * participants are required to have a documented, locally advanced or metastatic solid tumor malignancy, or non-hodgkin's lymphoma * that is refractory to standard therapy known to provide clinical benefit for their condition or * have demonstrated evidence of disease progression or relapse, via imaging, during or following standard therapy known to provide clinical benefit for their condition, or * have demonstrated intolerance to standard therapy known to provide clinical benefit for their condition. or * for which no standard therapy is available * measurable disease according to recist version 1.1. * malignancy not currently amenable to surgical intervention. * ecog performance status of 0, 1, or 2, and an anticipated life expectancy of ≥ 3 months at the time of signing the informed consent. * other protocol defined inclusion criteria could apply exclusion criteria: * participants with known cns or leptomeningeal metastases not controlled by prior surgery or radiotherapy, or symptoms suggesting cns involvement for which treatment is required. * other protocol defined exclusion criteria could apply
predictive nomogram for postoperative acute kidney injury in older patients undergoing noncardiac surgery

Conditions: Postoperative Acute Kidney Injury

Summary: postoperative acute kidney injury is associated increased risk of morbidity and mortality. older patients are at high risk of developing postoperative acute kidney injury. however, the incidence and associations of postoperative acute kidney injury in older patients are not well understood. this study aims to develop and validate a predictive nomogram for postoperative acute kidney injury in older patients undergoing noncardiac surgery.

postoperative acute kidney injury (aki) affects approximately 2% to 40% of patients undergoing cardiac and major noncardiac surgeries. older patients are more susceptible to renal impairment than younger patients. however, the incidence and associations of aki in older patients are rarely understood. generally, in-depth knowledge of risk factors and thus able to identify patients at high risk to develop postoperative aki is essential to optimize perioperative prevention and protection strategies. in this retrospective study, the investigators intend to develop and validate a predictive model for postoperative using the identified risk factors. the primary outcome is postoperative aki, which according to the kidney disease: improving global outcomes (kdigo) criterion, is defined as an absolute increase in serum creatinine of 0.3 mg/dl within 48 hours or a 1.5-fold increase from preoperative baseline within 7 days after surgery.

Eligibility criteria:
inclusion criteria: * patients aged 65 years and older exclusion criteria: * emergency operation * cardiac surgery * incomplete data * incomplete data * local anesthesia * preoperative renal failure or requirement for dialysis

Keywords: prediction model nomogram older noncardiac surgery